Как я вылечил подагру форум

The content of this leaflet has been checked and approved by the Israeli Ministry of Health.
Physician’s Prescribing Information

Etopan 400, 500, 600 mg XL Tablets

Composition:

Etopan XL 400 Etopan XL 500 Etopan XL 600
Each Extended Release
Tablet contains:
Each Extended Release
Tablet contains:
Each Extended Release
Tablet contains:
Etodolac 400 mg Etodolac 500 mg Etodolac 600 mg

Therapeutic class
Etodolac is a non steroidal anti-inflammatory drug (NSAID) that exhibits anti-
inflammatory, antirheumatic and analgesic activities.
Reported to be a preferential inhibitor of Cyclo-oxygenase 2 (COX-2).

Dosage form
Tablets

Mechanism of action
Non steroidal anti-inflammatory drugs inhibit the activity of the enzyme cyclo-oxygenase,
resulting in decreased formation of precursors of prostaglandins and thromboxanes from
arachidonic acid. Although the resultant decreaser in prostaglandin synthesis and activity
in various tissues may be responsible for many of the therapeutic effects of NSAIDs, other
actions may also contribute significantly to the therapeutic effects of these medications.
Antirheumatic — act via analgesic and anti-inflammatory mechanisms.
Analgesic — may block pain impulse generation via a peripheral action that may involve
reduction of the activity of prostaglandins, and possibly inhibition of the synthesis or
actions of other substances that sensitize pain receptors to mechanical or chemical
stimulation.
Antigout agent — act via analgesic and anti-inflammatory mechanisms.
Vascular headache suppressant — analgesic action may be involved in relief of headache.
Also, by reducing prostaglandin activity, may directly prevent or relieve certain types of
headaches thought to be caused by prostaglandin-induced dilation or constriction of
cerebral blood vessels.
Anti-inflammatory — exact mechanism have not been determined. May act peripherally in
inflamed tissue, probably by reducing prostaglandin activity in these tissues and possibly
by inhibiting the synthesis and/ or action of other local mediators of the inflammatory
response. Inhibition of leukocyte migration, inhibition of the release and / or actions of
The drug is also contra-indicated in patients with active peptic ulceration or with a history
of peptic ulcer disease.

Warnings
Risk benefit should be considered in patients with: A history of mild allergic reaction,
such as allergic rhinitis, urticaria or skin rash, induced by aspirin or other NSAIDs.
Inflammatory or ulcerative disease of the upper or lower gastrointestinal tract, including
Crohn’s disease, diverticulitis, peptic ulcer disease, active or history ulcerative colitis.
Hemophilia or other bleeding problems including coagulation or platelet function
disorders. Renal function impairment. Stomatitis.
Patient monitoring: Hematological determinations should be performed if symptoms of
blood dyscrasias occur. Chronically treated patients should be observed for the signs and
symptoms of GI ulceration and bleeding which may occur without warning symptoms.
Caution is required if Etodolac is administered to patients suffering from or with a
previous history of bronchial asthma.
Etodolac should be used with caution in patients with fluid retention, hypertension or heart
failure.

Use in Pregnancy
There are no adequate or well controlled studies in pregnant women. Etodolac should be
used during pregnancy only if the potential benefits justifies the potential risk for the fetus.
During first trimester: Alterations of limb development was demonstrated in animal
studies, but drug or dose-response relationship not established.
During second and third trimesters: Because of the known effects of NSAIDs on
parturition and on the human fetal cardiovascular system with respect to closure of the
ductus arterious, use during late pregnancy should be avoided.

Use in Lactation
Problems in humans have not been documented with most of the NSAIDs. It is not known
whether etodolac is distributed into breast milk.

Use in Pediatrics
This medicine is not usually recommended for administration to children / infants.

Adverse Reactions
Etodolac is well tolerated.
Medical attention needed only if continuing or are bothersome:
Incidence more frequent (3-9%) — Dizziness, mild to moderate headache, unusual
weakness with no other signs or symptoms, abdominal cramps, mild to moderate
abdominal pain or discomfort, bloated feeling or gas, diarrhea, indigestion, nausea.
Incidence less frequent (1-3%): nervousness or irritability, constipation.
Medical attention needed:
Incidence less frequent (1-3%) — Central nervous system effects mental depression.
Dermatological effects itching, skin rash. Digestive system effects gastritis (burning
feeling in chest or stomach, indigestion, tenderness in stomach area), gastrointestinal
bleeding or hemorrhage, melena (bloody stools), hematemesis (vomiting blood or material
that looks like coffee grounds), gastrointenstinal ulceration (severe pain, cramping or
burning; bloody or black tarry stools, vomiting of blood or material that looks like coffee
grounds, severe and continuing nausea, heartburn and / or indigestion. Genitourinary
effects dysuria (burning, painful or difficult urination), frequent urge to urinate.
Hypersensitivity reactions fever with or without chills. Ocular effects blurred or double
vision or any change in vision. Otic effects ringing or buzzing in ears.
Incidence rare (<1%): Cardiovascular effects congestive heart failure or exacerbation of,
increased blood pressure (cardiac arrhythmias — has been reported but a causal relationship
has not been established). Central nervous system effects syncope (fainting), (confusion —
has been reported but a causal relationship has not been established). Dermatological
effects bullous eruption / blisters, hives, Stevens-Johnson syndrome (desquamation has
been reported but a causal relationship has not been established). Digestive system effects
(colitis or exacerbation of, esophagitis — has been reported but a causal relationship has not
been established). Genitourinary effects (bleeding from vagina, unexplained / unexpected
/ unusually heavy menstrual, blood in urine, crystalluria, cystitis — has been reported but a
causal relationship has not been established). Hematological effects anemia, bruising,
thrombocytopenia with or without purpura (leukopenia — has been reported but a causal
relationship has not been established). Hepatic effects cholestatic hepatitis or jaundice,
toxic hepatitis or jaundice. Hypersensitivity reactions vasculitis, angioedema,
bronchospastic allergic reactions. Ocular effects (conjunctivitis — has been reported but a
causal relationship has not been established). Oral/perioral effects stomatitis, aphthous.
Renal effects fluid retention / edema, (intestinal nephritis — has been reported but a causal
relationship has not been established). Otic effects (decreased hearing or any change in
hearing — has been reported but a causal relationship has not been established). Shortness
of breath or troubled breathing — has been reported but a causal relationship has not been
established. Continuing thirst.

Drug Interactions
The following drug interactions and / or related problems have been reported:
Anticoagulants, coumarin or indandione-derivative or heparin or thrombolytic agents —
etodolac has been reported to potentiate the effects of coumarin or indandione-derivative
anticoagulants that may result from displacement of the anticoagulant from protein
binding sites. Inhibition of platelet aggregation by NSAIDs, and the possibility of NSAID-
induced gastrointestinal ulceration or bleeding, may be hazardous to patients receiving
anticoagulant or thrombolytic therapy. Acetyl salycilic acid or two or more NSAIDs
concurrently — alteration of pharmacokinetic profile of at least one of the medications, may
alter the therapeutic effect and/ or increase the risk of adverse effects — may increase the
risk of gastrointestinal toxicity, ulceration or hemorrhage, bleeding. Cefamandole,
cefoperazone, cefotetan, plicamycin, valproic acid — may cause hypoprothrombinemia, in
addition plicamycin or valproic acid may inhibit platelet aggregation. Concurrent use with
a NSAID may increase the risk of bleeding because of additive interferences with platelet
function and/ or potential occurrence of NSAID-induced GI ulceration or hemorrhage.
Cyclosporine, digitalis glicosides, methotrexate, lithium — etodolac, like other NSAIDs,
through effects on renal prostaglandins, may cause changes in the elimination of these
drugs leading to elevated serum levels and increased toxicity. Nephrotoxicity associated
with cyclosporine may also be enhanced. Patients receiving these drugs who are given
etodolac or any other NSAID and particulary those patients with altered renal function,
should be observed for the development of the specific toxicities of these drugs. Diuretics
— etodolac should be used with caution in patients receiving diuretics, who have cardiac,
renal or hepatic failure. Probenecid may decrease excretion and increase serum
concentrations of NSAIDs, possibly enhancing effectiveness and/ or increasing the
potential for toxicity; a decrease in dosage of the NSAID may be necessary if adverse
effects occur.
Corticosteroids oral glucocorticoid or Corticotropin (chronic therapeutic use) may
increase risk of gastrointestinal side effects, including ulceration or hemorrhage; however,
concurrent use in the treatment of arthritis may provide additional therapeutic benefit and
permit reduction of glucocorticoid or corticotropin dosage
1
.

Precautions
The antipyretic, analgesic and anti-inflammatory actions of NSAIDs may mask symptoms
of the occurrence or worsening of infections. Renal effect — renal toxicity encountered
with etodolac, as with other NSAIDs, is seen in patients with conditions in which renal
prostaglandins have a supportive role in the maintenance of renal perfusion. In these
patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-
dependent reduction in prostaglandin formation and, secondarily, in renal blood flow,
which may precipitate overt renal decompensation. Patients at greatest risk of this reaction
are those with impaired renal function, heart failure, liver dysfunction, those taking
diuretics, and the elderly. Discontinuation of NSAIDs therapy is usually followed by
recovery to the pretreatment state. Etodolac metabolites are eliminated primarily by the
kidneys. The extent to which the inactive glucoronide metabolites may accumulate in
patients with renal failure has not been studied. As with other drugs whose metabolites are
excreted by the kidney, the possibility that adverse reactions may be attributable to these
metabolites should be considered. About 10% of patients with asthma may have aspirin-
sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthmas has been
associated with severe bronchospasm which can be fatal. Since cross reactivity, including
bronchospasm, between aspirin and other nonsteroidal anti-inflammatory drugs has been
reported in such aspirin-sensitive patients, etodolac should not be administered to patients
with this form of aspirin-sensitive and should be used with caution in all patients with pre-
existing asthma. Hepatic effects — As with all NSAIDs, borderline elevations of one or
more liver tests may occur in up to 15% of patients. These abnormalities may disappear,
remain essentially unchanged or progress with continued therapy. A patient with
symptoms and/ or signs suggesting liver dysfunction or in whom an abnormal liver test
has occurred, should be evaluated for evidence of the development of a more severe
hepatic reaction while on therapy with etodolac. Although such reactions are rare, if
abnormal liver tests persist or worsen, if clinical signs and symptoms consistent with liver
disease develop or if systemic manifestations occur (e.g. eosinophilia, rash), etodolac
should be discontinued. Hematological effects — anemia is sometimes seen in patients
receiving etodolac or other NSAIDs. This may be due to fluid retention ,gastrointestinal
blood loss, or an incompletely described effect upon erythropoiesis. Patients on long term
treatment with NSAIDs, including etodolac, should have their hemoglobin or hematocrit
checked if they develop signs or symptoms of anemia. All drugs which inhibit the
biosynthesis of prostaglandins may interfere to some extent with platelet function and
vascular responses to bleeding. Patients receiving etodolac who may be adversely affected
by such actions should be carefully observed. Fluid retention — fluid retention and edema
have been observed in some patients taking etodolac. Therefore, as with other NSAIDs,
etodolac should be used with caution in patients with fluid retention, hypertension or heart
failure. GI ulceration, bleeding and perforation — physicians should be alert for ulceration
and bleeding in patients treated chronically with NSAIDs even in the absence of previous
GI tract symptoms. Prior history of serious GI events and other risk factors known to be
associated with peptic ulcer disease, such as alcoholism, smoking, etc. have been
associated with increased incidence of these side effects. Elderly or debilitated patients
seem to tolerate ulceration or bleeding less well than other individuals, and most
spontaneous reports of fatal GI events are in this population. High doses of any NSAIDs
probably carry a greater risk of these reactions, thus sufficient benefit should be
anticipated to offset the potential increased risk of GI toxicity when considering use of
relatively large doses (within recommended dosage range).

Dosage and Administration
400mg XL One to two tablets twice daily but no more than three tablets a day.
600mg XL One tablet once or twice daily.
The total daily dose of Etopan XL should not exceed 1,200mg.

As with other NSAIDs, the lowest dose and longest interval should be sought for each
patient. Therefore, after observing the response to initial therapy with Etopan XL, the dose
and frequency should be adjusted to suit individual patient’s needs (tolerance and
response). In responsive patients, partial symptomatic relief of symptoms usually occurs
within 1 or 2 weeks, although maximum effectiveness may occur only after several weeks
of therapy.
During long-term administration the dose of Etopan XL may be adjusted, up or down,
depending on the patient’s clinical response (maximum dose 1200 mg/day).
As with other NSAIDs, Etopan XL is preferably taken after meals or with food or antacids
to reduce gastrointestinal irritation, especially during chronic use. However, for faster
absorption when a rapid initial effect is required, the first 1 or 2 doses may be taken 30
minutes before meals or at least 2 hours after meals. If an antacid is taken concurrently, an
aluminum and magnesium-containing formulation may be preferred. It is recommended to
take Etopan XL tablets with a full glass of water and that the patient remain in an upright
position for 15-30 minutes after administration. Patients should be advised to avoid
alcoholic beverages while under treatment with this medicine.

Overdosage
Signs and symptoms following acute NSAIDs overdose are usually limited to: lethargy,
drowsiness, nausea, vomiting and epigastric pain, which are generally reversible with
supportive care. Hypotension, acute renal failure and respiratory depression may occur but
are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of
NSAIDs and may occur following overdose.
Treatment There are no specific antidotes.
1. Emptying the stomach via induction of emesis (in alert patients only, syrup ipecac is not
recommended) or gastric lavage.
2. Administering activated charcoal (preferably within 2 hours following overdose
ingestion or repeatedly).
3. Administering antacids.
4. Instituting symptomatic and other supportive treatment as necessary (certain adverse
reactions may respond to glucocorticoid administration).
5. Administering as required: plasma volume expanders for severe hypotension, diazepam/
other appropriate benzodiazepine anti convulsant for convulsions, vitamin K1 for
hypoprothrombinemia and/ or dopamine plus dobutamine I.V., to prevent or reverse early
indications of renal failure. Patients being discharged after initial treatment should be
informed of possible presenting symptoms and advised to seek immediate treatment if
they occur.

Diagnostic Interference
Phenolic metabolites of etodolac may cause false-positive results in urine bilirubin
determination. False-positive test results may occur with dipstick method of urine ketones
determinations.

Storage
Store in a cool and dry place.

Manufacturer
Taro Pharmaceutical Industries Ltd., Haifa Bay 26110

revised: 12/2004